Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels.
The success of CMSA has been largely due to the deal with Cipla India, which recently made an offer of R10 per share.
The drugs manufacturing industry is on a state of alert following two landmark developments over a cancer treatment medicine.
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically.
India serves as the company's R&D hub as it morphs into a health tech major.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances